The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The protections extend through at least 2035, with the potential for further extensions
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Subscribe To Our Newsletter & Stay Updated
